Becker's Healthcare September 29, 2022
Pharmaceutical company Qnovia has raised $17 million in series A funding.
Qnovia specializes in creating inhaled therapeutics used to treat nicotine addiction and cardiopulmonary diseases. The company plans to use the funding to advance its nicotine replacement therapy drug through FDA trials and begin human trials in 2023, according to the Sept. 28 Qnovia news release.
The funding round was led by Blue Ledge Capital.
“This series A closing represents a major milestone...